These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33605020)

  • 1. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
    Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
    J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
    Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
    Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
    Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.
    Hill H; Robinson M; Lu L; Slaughter D; Amin A; Mileham K; Patel JN
    Thromb Res; 2021 Dec; 208():71-78. PubMed ID: 34742139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
    Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
    J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score.
    Castellón Rubio VE; Segura PP; Muñoz A; Farré AL; Ruiz LC; Lorente JA
    Thromb Res; 2020 Dec; 196():349-354. PubMed ID: 32977135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
    Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy.
    Bjørnhart B; Kristiansen C; Asmussen J; Hansen KH; Wedervang K; Jørgensen TL; Herrstedt J; Schytte T
    Thromb Res; 2023 Jan; 221():164-172. PubMed ID: 36396518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients.
    He X; Wei SN; Qin WW; Geng N; Li B; Song S; Wang P
    Expert Rev Hematol; 2023; 16(12):1135-1142. PubMed ID: 37883026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy.
    Li A; May SB; La J; Martens KL; Amos CI; Flowers CR; Do NV; Brophy MT; Chitalia V; Ravid K; Gaziano JM; Fillmore NR
    Am J Hematol; 2023 Aug; 98(8):1214-1222. PubMed ID: 37161855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
    Kim HW; Kim JS; Lee SH
    Lung Cancer; 2021 Aug; 158():107-114. PubMed ID: 34146757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis.
    Giustozzi M; Becattini C; Roila F; Agnelli G; Mandalà M
    Cancer Treat Rev; 2021 Nov; 100():102280. PubMed ID: 34438237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
    Icht O; Leader A; Batat E; Yosef L; Shochat T; Goldstein DA; Dudnik E; Spectre G; Raanani P; Hammerman A; Zer A
    Oncologist; 2023 Jun; 28(6):e391-e396. PubMed ID: 37014824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study.
    Overvad TF; Skjøth F; Piazza G; Noble S; Ording AG; Larsen TB; Nielsen PB
    J Thromb Haemost; 2022 Dec; 20(12):2921-2929. PubMed ID: 36112135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.
    Deschênes-Simard X; Richard C; Galland L; Blais F; Desilets A; Malo J; Cvetkovic L; Belkaid W; Elkrief A; Gagné A; Hamel MA; Orain M; Joubert P; Ghiringhelli F; Routy B; Blais N
    Thromb Res; 2021 Sep; 205():29-39. PubMed ID: 34246011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of risk assessment scores in predicting venous thromboembolism in patients with lung cancer receiving immune checkpoint inhibitors.
    Zhang J; Xie Y; Yang L; Yang M; Xu R; Liu D
    BMC Pulm Med; 2024 Oct; 24(1):507. PubMed ID: 39390440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence of venous thromboembolism among patients with primary lung cancer.
    Chew HK; Davies AM; Wun T; Harvey D; Zhou H; White RH
    J Thromb Haemost; 2008 Apr; 6(4):601-8. PubMed ID: 18208538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors.
    Kartolo A; Yeung C; Moffat GT; Hanna L; Hopman W; Baetz T
    Immunotherapy; 2022 Jan; 14(1):23-30. PubMed ID: 34758641
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer.
    Parker A; Peterson E; Lee AYY; de Wit C; Carrier M; Polley G; Tien J; Wu C
    J Thromb Haemost; 2018 Jul; 16(7):1321-1326. PubMed ID: 29733498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.